CoChat
Cited by 101

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease

Open access
CREED, T. J., PROBERT, C. S. J., NORMAN, M. N., MOORGHEN, M., SHEPHERD, N. A., HEARING, S. D., DAYAN, C. M., THE BASBUC INVESTIGATORS · 2006 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Preliminary data have suggested that interleukin‐2 receptor blockade with basiliximab may increase steroid sensitivity. We have previously reported a small case series demonstrating the potential of basiliximab as a novel agent for the treatment of steroid‐resistant ulcerative colitis. Aim: To report further experience of the efficacy and safety of treatment with the interleukin‐2 receptor blocking monoclonal antibody basiliximab, in addition to steroids, for the treatment of severe and moderate steroid‐resistant ulcerative colitis. Methods: Twenty patients were enrolled – 13 patients with moderate steroid‐resistant ulcerative colitis (Ulcerative Colitis Symptom Score: ≥6) and seven patients with severe steroid‐resistant ulcerative colitis. All were given a single dose of 40 mg basiliximab plus standard steroid therapy in an open‐label, uncontrolled trial. Primary end point was clinical remission within 8 weeks (Ulcerative Colitis Symptom Score: ≤2). Results: Within 8 weeks, 10 of 20 (50%) patients achieved clinical remission (seven of 13 moderate, and three of seven severe). At 24 weeks, 13 of 20 (65%) patients were in clinical remission. Five patients required colectomy (four severe, one moderate ulcerative colitis) and one required rescue ciclosporin (moderate ulcerative colitis). Two patients developed herpes zoster, but treatment was generally well tolerated. Conclusions: Basiliximab appears to promote prolonged remission after a single treatment. Taken in combination with previously reported data, basiliximab shows particular promise in moderate steroid‐resistant ulcerative colitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2006.02904.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 101

Metadata

Authors
CREED, T. J., PROBERT, C. S. J., NORMAN, M. N., MOORGHEN, M., SHEPHERD, N. A., HEARING, S. D., DAYAN, C. M., & THE BASBUC INVESTIGATORS
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2006-04-28
Volume
23
Issue
10
Pages
1435-1442
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1985633590
Cited by
101
References
1
FWCI
6.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease. https://app.cochat.ai/papers/10.1111/j.1365-2036.2006.02904.x
The paper
CREED, T. J., PROBERT, C. S. J., NORMAN, M. N., MOORGHEN, M., SHEPHERD, N. A., HEARING, S. D., DAYAN, C. M., & THE BASBUC INVESTIGATORS. (2006). Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.02904.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.